EIF3B Promotes KRAS Gene Mutation‐Driven Colon Adenocarcinoma Progression Through the TBK1 and PI3K/AKT Signaling Pathways
Journal of Biochemical and Molecular Toxicology · 2025
DOI: 10.1002/jbt.70353 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2025. Verfasst von Chongren Ren und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical …. Hauptthemen laut MEDLINE: Eukaryotic Initiation Factor-3, Proto-Oncogene Proteins p21(ras), Protein Serine-Threonine Kinases, Signal Transduction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: This study was funded by the 'Lvliang City key research and development project' of Shanxi Province (NO.2022SHFZ05) and the 'Science and Technology Funding Pro….
Abstract (Originalsprache)
Therapeutic targets involved in multiple signaling pathways offer promising treatment options for cancers driven by KRAS gene mutations (KRAS mut ). EIF3B has emerged as a potential therapeutic target for colorectal cancer (CRC). To elucidate the role of EIF3B and its interactions with potential targets in CRC, we utilized bioinformatics techniques alongside clinicopathological analyses. RNA sequencing identified signaling pathways associated with EIF3B. The expression levels of relevant genes and their associated pathways were measured using RT‐qPCR and western blot analyses. RNA immunoprecipitation (RIP) confirmed the interactions between EIF3B and these specific genes. Analysis of data from The Cancer Genome Atlas (TCGA), combined with clinicopathological studies, revealed significantly elevated levels of EIF3B and TBK1 mRNA and proteins in KRAS mut colorectal adenocarcinoma (COAD) compared to normal tissues. Silencing EIF3B inhibited the proliferation and progression of KRAS mut COAD and disrupted the TBK1, PI3K/AKT, and JAK2/STAT3 pathways. EIF3B also regulated the translation of TBK1 and PIK3CA. Targeting EIF3B presents a novel approach to modulating various cellular signaling pathways, offering a promising therapeutic strategy for patients with KRAS mut COAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.
- Department of Neurology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.
ORCID-Profile: Dujuan Cao
Förderung
- This study was funded by the 'Lvliang City key research and development project' of Shanxi Province (NO.2022SHFZ05) and the 'Science and Technology Funding Pro…
Zitieren
APA
Ren, C., Qin, Y., Cao, D., Ren, X., Zhao, H., Han, J., & Du, G. (2025). EIF3B Promotes KRAS Gene Mutation‐Driven Colon Adenocarcinoma Progression Through the TBK1 and PI3K/AKT Signaling Pathways. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70353
Vancouver
Ren C, Qin Y, Cao D, Ren X, Zhao H, Han J, et al. EIF3B Promotes KRAS Gene Mutation‐Driven Colon Adenocarcinoma Progression Through the TBK1 and PI3K/AKT Signaling Pathways. Journal of Biochemical and Molecular Toxicology. 2025. doi:10.1002/jbt.70353
BibTeX
@article{Ren2025,
author = {Ren, Chongren and Qin, Yaxin and Cao, Dujuan and Ren, Xiaojing and Zhao, Haoliang and Han, Jianli and Du, Gang},
title = {EIF3B Promotes KRAS Gene Mutation‐Driven Colon Adenocarcinoma Progression Through the TBK1 and PI3K/AKT Signaling Pathways},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2025},
doi = {10.1002/jbt.70353}
}
EUVIMED